Member Info for mark-expat

.... results out .. imo , the future of rail franchises maintain the hammer. Servicing debt is not of issue as earnings hold. Not a high flyer but worth looking at the likes of such for the longer term.

Whilst just a short piece , much of what is stated will drag on GS's expectations. For sure , should equities fly , then LGEN's exposure will be a positive , but , I would have thought that the market will remain cautious on LGEN , gl http://www.dailyexpress.co.uk/posts/view/109572

http://business.timesonline.co.uk/tol/business/industry_sectors/banking_and_finance/article6565859.ece#cid=OTC-RSS&attr=1185799 ... increased volumes and some good volatility might start appearing on this one

http://business.timesonline.co.uk/tol/business/industry_sectors/media/article6550096.ece#cid=OTC-RSS&attr=1185799

... as they have made a loss for the last 6 years , does it really matter? Such , imo , be a bonus, so , either you are an investor , in which case such will only add to continued demise or you be an employee of which you should know better.

...either you take the £1k hit , or weather the turbulence by shorting any further drop in altitude.

I bet they have separate canteens and urinals

- agreed the Chikou span is now nearing or resting on todays closing price but is not yet below - if it went below it is a signal that the price of the asset is getting exhausted and is likely to experience a pullback. However , the MACD and Ichimoku clearly still show weakness ahead , what charts are you using?

by Goldmans whilst Moody's focus on cutting credit ratings on others

http://www.dailyexpress.co.uk/posts/view/107869 true to form

http://uk.reuters.com/article/businessNews/idUKTRE55C0RR20090613 - it will be really interesting to see how LBG keeps the likes of Santander from taking market share whilst LBG unbundles itself. I have really enjoyed the last few months in financials and take my hat off top the likes of Standard Chartered and Santander but give AIB and BOI the slap on the back for their recovery , however long it lasts until any retrace kicks in.

... over last week or so , cashed in and might well try to get some of these on a hopeful little retrace for the self-trade stock ISA that HeadForTheHills kindly eluded to , thanks again for the info and discussion board you set up HFTH , have a good weekend all

http://www.ise.ie/app/announcementDetails.asp?ID=2177286 http://www.rte.ie/business/2009/0611/aib.html

... maybe it says to take double the dose of the max strength in small print somewhere , lol , thats marketing for you!

agreed , its kind of moved up my radar for varying reasons and fully accept that (on a weekly ichi basis) growth in SP will remain always on a lowly recent historical basis. I remain focused on the main indices at the moment and am starting to sharpen the pencils on a few ducks that I am lining up to hopefully transfer profits across a spread from the low risk reasonable yield with a likely recovery of SP to absolute high risk stocks bang and you are gone stocks , so starting with the low end first , feel like GSK could well sit at that end. Anyway , good to chat , thanks for your feedback , always welcomed and respected , gl

hiya, I was , as you were likely aware , a shorter of RBS B4 the ban and continued to add to my short position when lifted in the states. It was only when it got to the bottom and it became clear that HMG would not let RBS fail but support it that I closed and went in long. I have focused on RBS , amongst all other banks , pretty much period and was very surprised by the Q1 results. Should the interims be consistent with Q1 , then the market concensous of estimates will have to be revised dramatically and a re-rating given. The debt and HMG issue will persist to weigh down , but as I have mentioned B4 , I would sooner work with HMG as a shareholder when on the back foot restructuring rather than not and see the net asset base of RBS as both desirable , at valuations of mark to market and available to exercise continued disposal options. Whilst such may reduce earnings going forward , should RBS best manage to offload non core structural assets and associated costs and utilise such revenue realised to recapitalise and then share buy back primarily direct from HMG , then , RBS , imo , could start to outperform Barclays and build up to become a well placed no.3 behind HSBA/STAN.

an interesting read alongside many others that we all cast our eyes over http://www.telegraph.co.uk/finance/personalfinance/investing/5431622/Recession-95pc-of-finance-professionals-expect-downturn-to-continue.html

There is lots of positive news flow surrounding developments re GSK but the stock is bouncing around its lows ... at these levels a likely c.6% pa dividend going forward is pretty much a certain and whilst GSK will certainly not be in the 'bagger' brigade , I would also consider that growth going forward in the SP more than likely. A safe place for a steady return? http://www.dailyexpress.co.uk/posts/view/105068

http://uk.reuters.com/article/businessNews/idUKTRE5510M620090602?feedType=RSS&feedName=businessNews - well , well , well , is it not amazing how many CEO's of very large companies take a considerable amount of time longer than most 11 year olds to formulate the same conclusion.

http://business.timesonline.co.uk/tol/business/industry_sectors/health/article6401710.ece#cid=OTC-RSS&attr=1185799 should the phase 3 trials prove successful , a vaccine against the worlds biggest killer will be a must have for those who live in some of the most populated areas of the world effected by malaria , equally , I am sure that the worlds armed forces and all health / disaster folk would like a jab or two. Always staggered by some companies valuations , but with a c.5% + annual dividend and floating around lows with some brokers suggesting valuations of c.40% above current SP value , it only needs the likes of these trials to eventually come into the marketplace to justify values. If you have cash in hand , I would say that whilst not dynamic , a safe defensive stock to introduce or add too at current valuation and upon any further weakness that will yield a reasonable dividend and has every chance of returning steady SP growth.